Antibody Engineering Meeting

Warlo at aol.com Warlo at aol.com
Sun Apr 27 11:38:28 EST 1997


ANTIBODY ENGINEERING 97

Place:  San Francisco, California, USA,
            Holiday Inn,  UNION SQUARE

DATE:   September 21-24, 1997

KEYNOTE:   Richarad A. Lerner,  The SCRIPPS RESEACH INSTITUTE



THERAPEUTIC ANTIBODY MEETING 97

DATES:		September 21-24, 1997
PLACE:		Holiday Inn; Union Square; San Francisco, CA, USA
SPONSOR:		Palo Alto Institute of Molecular Medicine
ORGANIZERS:
	
			Dennis R. Burton PhD
			The Scripps Research Institute

			James W. Larrick MD PhD
			Palo Alto Institute of Molecular Medicine

PURPOSE:

This meeting has two principal aims. The first is to serve as a forum for the
presentation and discussion of new findings in the antibody field.  The
second is to review and discuss many aspects of the overall direction of
antibody research and application. For the second aim, we have asked leaders
in their areas to include a strong component dedicated to a critical
overview.  Also included with each session is an extended panel discussion
during which attendees are encouraged to ask questions and air issues from
the floor.  It is hoped that the meeting will be both thought provoking and
influential.

Sunday September 21, 1997	8 pm

	Arrival

	KEYNOTE ADDRESS:	Dr. Richard A. Lerner
					The Scripps Research Institute
					"Catalytic Antibodies"

THERAPEUTIC ANTIBODY MEETING 97

TENTATIVE PROGRAM--Invited Speakers

Monday September 22, 1997	8:30 am

Sessions:

1.	Antibody interaction with antigen
2.	The generation of human antibodies
3.	Antibodies or modified antibodies as effector molecules
4.	Antibodies in the study, prophylaxis and therapy of disease

1. 	Antibody interaction with antigen

Ian Wilson:  How should we view this interaction: lock and key vs induced
fit. What does this mean for antibody "design" e.g. naive library
construction.

Peter Schultz: The concept that affinity maturation results from fixing of
certain conformations.

Peter Colman: Influenza virus neuraminidase: structure, antibodies, and
inhibitors. Important data relating to changes in antibody structure on
antigen binding

Roy Mariuzza: The structural and energetic basis of idiotype-anti-idiotype
recognition. Beautiful work showing that for an Ab-Ag and Ab-anti-Id the Ab
contact residues are similar but the energetic contributions of these
residues to binding are quite different.

Cyrus Chothia: The prediction of antibody combining sites. Canonical
structures. Motifs. What can and can not be done with AB engineering.

Michael Neuberger:  Mechanisms of somatic mutation in antibodies. Can we
harness this in vitro in the foreseeable future?

Neil Greenspan:  The measurement of antibody affinity. Significance of
affinity in vivo. What are the normal ranges? Cooperativity in antibody
binding.

Jamie Scott :  Epitope definition using peptide phage display libraries.

Richard Houghten: Epitope definition using synthetic peptide libraries

Chair of discussion :  David Davies


2. 	The generation of human antibodies

Objective talks with a strong review component.

Peter Hudson: overview, introduction to various methods, comparison, comments
on humanized antibodies, chimeric, CDR grafting, antibodies by cellular
routes, EBV transformation, hybridomas

Andrew Griffiths: from naive/synthetic phage display libraries

Peter Pack (Morphosys): from synthetic phage display libraries

Paul Parren: from immune phage display libraries

Ton Logtenberg: selection on cells

Carl Borrebaeck: library selection methods, SIP, CLAP

Jim Marks: The in vitro improvement of antibody affinity

Carlos Barbas: The in vitro improvement of antibody affinity

Aya Jacobvits: from transgenic mice

Chair of Discussion:	Andreas Pluckthun


3. 	Antibodies or modified antibodies as effector molecules

Sherie Morrison: Natural effector systems. How good is complement at killing
antibody-targeted cells and viruses in vivo in humans. What is the role of Fc
receptors. Which Fc receptors, which cells? Decay accelerating factor.

Richard Junghans: The metabolic fate of administered antibody. The Brambell
receptor, molecular basis of catabolism, all seen in new light now receptor
is identified.

Hermann Waldman: Antibodies with enhanced effector activity. 

Ralph Reisfeld : Antibody-cytokine fusions

Ira Pastan: Immunotoxins

Michael Pfreundschuh: Bifunctional antibodies 

Tom Smith: Structural studies on the mechanism of antibody-mediated
neutralization of rhinovirus. 

Wayne Maracso: Intracellullar antibodies

Peter Senter: ADEPT

Zelig Eshhar: T bodies

Chair of Discussion : Dennis Burton


4. 	Antibodies in the study, prophylaxis and therapy of disease

Arturo Casedvall:  Historical perspective of the use of antibodies in
infectious disease.

Nancy Haigwood: Passive immunotherapy in the SIV model

Dennis Burton: The antibody response to HIV-1

Anthony Williamson : Antibodies and the prion problem.

Marty Rosenberg: RSV prophylaxis;  other targets under study at SKB

Speaker : anti-TNF

Paula Jardieu: Anti-IgE receptor


Chair of Discussion : Jim Larrick




More information about the Immuno mailing list